Shares of Biocon surged over 7% in early trade on January 7, following an upgrade from international brokerage Jefferies. The firm raised its rating on Biocon to 'underperform' and increased its target price by 43% to Rs 400, citing positive developments around the regulatory approval of the company’s manufacturing facility in Bengaluru. BIG FDA BOOST The key trigger for the …
